BIT BIO Discovery — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

BIT BIO Discovery is a Vienna-based biotech firm that has developed a proprietary drug discovery platform combining human iPSC-derived cell models with CRISPR knockout, activation, and interference technologies. The company offers its scalable screening services to partners, utilizing either customer-supplied cell models or its proprietary ioCells™, to identify novel targets for small molecule drugs in oncology and immunology. Founded in 2018 as a joint venture, it is led by a seasoned management team with deep expertise in CRISPR, stem cell biology, and biotech corporate development. BIT BIO Discovery positions itself as a trusted partner for pharmaceutical companies and researchers in the pre-clinical discovery phase.

OncologyImmunology

Technology Platform

A functional genomics screening platform combining human induced pluripotent stem cell (iPSC)-derived disease models (including proprietary ioCells™ powered by opti-ox™ reprogramming) with CRISPR knockout, activation, and interference (CRISPRko/a/i) technologies for unbiased, high-throughput target discovery and validation.

Opportunities

The growing demand for human-relevant, predictive disease models in pharmaceutical R&D presents a major opportunity.

BIT BIO Discovery can capitalize on this by securing partnerships with large pharma companies seeking to de-risk early discovery in oncology and immunology.

Further expansion of its ioCells™ portfolio into new therapeutic cell types could open additional disease areas and revenue streams.

Risk Factors

Key risks include competition from other CROs and internal pharma capabilities in iPSC/CRISPR screening, potential technical limitations in the predictive power of iPSC-derived models for certain diseases, and reliance on a limited number of partnership deals for revenue as a young, private company.

Execution risk in delivering complex screening projects is also present.

Competitive Landscape

BIT BIO Discovery competes with other specialized contract research organizations (CROs) offering CRISPR screening services (e.g., Horizon Discovery, Synthego), as well as companies focusing on iPSC-derived disease models and services. Its key differentiation is the integrated offering of ready-made, consistent iPSC-derived cells (ioCells™) with bespoke CRISPR screening. Large pharmaceutical companies are also developing internal capabilities in this space, posing a competitive threat.

More companies in Diagnostics & Precision Medicine →More companies in Austria →